Chapter title |
Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
|
---|---|
Chapter number | 16 |
Book title |
Gene Therapy of Cancer
|
Published in |
Advances in experimental medicine and biology, January 1998
|
DOI | 10.1007/978-1-4615-5357-1_16 |
Pubmed ID | |
Book ISBNs |
978-1-4613-7444-2, 978-1-4615-5357-1
|
Authors |
P Karle, P Müller, R Renz, R Jesnowski, R Saller, K von Rombs, H Nizze, S Liebe, W H Günzburg, B Salmons, M Löhr, Karle, Peter, Müller, Petra, Renz, Renate, Jesnowski, Ralf, Saller, Robert, Rombs, Kerstin, Nizze, Horst, Liebe, Stefan, Günzburg, Walter H., Salmons, Brian, Löhr, Matthias, Peter Karle, Petra Müller, Renate Renz, Ralf Jesnowski, Robert Saller, Kerstin von Rombs, Horst Nizze, Stefan Liebe, Walter H. Günzburg, Brian Salmons, Matthias Löhr, von Rombs, Kerstin |
Abstract |
The prognosis of pancreatic adenocarcinoma is poor and current treatment is for the most part ineffective. We describe here a novel treatment strategy using a mouse model system for pancreatic cancer. Human embryonic epithelial cells have been genetically modified to express the cytochrome P450 2B1 enzyme under the control of a CMV immediate-early promoter. This CYP2B1 gene converts oxazaphosphorines (ifosfamide or cyclophosphamide) to their active cytotoxic compounds, phosphoramide mustard, which alkylates DNA, and acrolein, which alkylates proteins. A number of assays were performed to demonstrate the CYP2B1 gene function as well as toxic effects on neighbouring cells (bystander effect). The cells were then encapsulated in a cellulose sulphate formulation shown to be well tolerated in the pancreas of immunocompetent mice, and injected 1 cm away from pre-established tumours derived from a human pancreatic tumour cell line (PaCa-44). Intraperitoneal administration of low-dose ifosfamide to tumour bearing mice that received the encapsulated cells results in partial or even complete tumour ablation. Such an in situ chemotherapy strategy utilizing genetically modified cells in an immunoprotected environment may prove useful for solid tumour therapy in man. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 11 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 3 | 27% |
Researcher | 2 | 18% |
Student > Ph. D. Student | 1 | 9% |
Student > Bachelor | 1 | 9% |
Student > Master | 1 | 9% |
Other | 1 | 9% |
Unknown | 2 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 3 | 27% |
Agricultural and Biological Sciences | 2 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
Medicine and Dentistry | 1 | 9% |
Engineering | 1 | 9% |
Other | 0 | 0% |
Unknown | 3 | 27% |